Primo A 50 mg 100 tabs Hutech Labs USA
$250.00
Product Short Description
Primo A 50 mg 100 Tablets Hutech Labs USA delivers methenolone acetate (C22H32O3), the DHT-derived anabolic steroid, at premium oral 50 mg strength in a high-count sealed bottle matching DEA Schedule III controlled substance standards. Domestic U.S. production serves institutional performance channels exclusively.
Product Overview
Hutech Labs USA’s Primo A 50 mg presents methenolone acetate, the 1-methylated DHT anabolic exhibiting mild anabolic properties and minimal androgenic effects, in scored tablets for institutional performance catalogs. The 100-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring precise potency declaration and batch traceability essential for DEA-regulated workflows.
Domestic manufacturing eliminates customs exposure while maintaining pharmaceutical-grade specifications distinguishing legitimate Schedule III product from underground conversions. This oral acetate ester serves advanced resellers managing structured controlled substance inventories rather than injectable enanthate or general supplement crossover.
Primo A targets verified CIII ecosystems emphasizing commercial positioning without protocols or claims.
Brand & Manufacturer Information
Hutech Labs USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. Primo A maintains catalog continuity alongside Hutech Anavar with consistent 50 mg tablet morphology authenticating legitimate institutional supply.
U.S. warehousing supports DEA Form 222 record-keeping across encrypted platforms confirming methenolone acetate identity/potency.
Active Compound Information
Contains methenolone acetate (1-methyl-17β-acetoxy-5α-androst-1-en-3-one), 1-methylated DHT derivative featuring mild anabolic:androgenic ratio (~88:44-57) with acetate ester enabling oral bioavailability and short ~4-6 hour half-life. DEA Schedule III (21 CFR 1308.13) classification reflects controlled substance status despite lower hepatotoxicity versus 17α-alkylated alternatives.
50 mg oral strength positions institutional-grade while maintaining DHT backbone without aromatization. WADA S1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Primo A 50 mg 100 Tablets Hutech Labs USA |
| Active Compound | Methenolone acetate (C22H32O3) |
| Strength | 50 mg per tablet |
| Quantity | 100 tablets per bottle |
| Form | Oral tablets |
| Category | DEA Schedule III controlled substance |
| Packaging | Tamper-evident HDPE bottle |
| Label Elements | 50 mg declaration, batch/expiry, CIII warnings |
Quality Control & Testing Standards
50 mg methenolone acetate requires potency assay, dissolution profiling, and acetate ester hydrolysis stability verification. Hutech batch documentation confirms C22H32O3 identity and Schedule III-compliant excipients distinguishing legitimate production from underground alternatives.
100-tablet institutional bottling prevents diversion matching DEA protocols; domestic warehousing maintains product integrity.
Intended Use & Market Positioning
Serves CIII-licensed institutional researchers managing DEA Schedule III oral anabolic inventories exclusively. 50 mg/100-tab excludes crossover within premium domestic catalogs. No protocols represented.
Legal & Regulatory Disclaimer
Methenolone acetate constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.
You must be logged in to post a review.
Reviews
There are no reviews yet.